Evidence map›Paper›PMID 32636302›Full record

ArticleThe Journal of biological chemistry2020

The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.

Megan E Arrington, Brenda Temple, Antje Schaefer, Sharon L Campbell

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. How Functional Variants Reconfigure the Rac2 Conformational Landscape.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Megan E ArringtonDepartment of Chemistry, University of North Carolina, Chapel Hill, North Carolina, USA.
Brenda TempleDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA; R. L. Juliano Structural Bioinformatics Core Facility, University of North Carolina, Chapel Hill, North Carolina, USA.
Antje SchaeferDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
Sharon L CampbellDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. Electronic address: campbesl@med.unc.edu.
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Project 4: The role of codon bias in RAS tumorigenesisP01CA203657 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUNTER, CHRISTOPHER M · 2016 to 2020
$7.9M
Structure and Mechanism of G-proteins and cell adhesion proteins in regulation of cell growth and motilityR35GM134962 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Sharon L Campbell · 2020 to 2026
$4.2M
The Role of RHOA in Diffuse Gastric CancerR01CA224428 · NCI · DANA-FARBER CANCER INST · PI DER, CHANNING J., WANG, TIMOTHY CRAGIN · 2018 to 2022
$3.6M
Mechanisms of vinculin activation and force transmissionR01GM115597 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAMPBELL, SHARON L · 2016 to 2019
$1.6M
Role of the Tail Domain in Vinculin FunctionR01GM081764 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAMPBELL, SHARON L · 2009 to 2010
$222k
NCI NIH HHS P01 CA203657NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA224428NIGMS NIH HHS R35 GM134962
6 · The paper itself

Abstract

The RAS-related C3 botulinum toxin substrate 2 (RAC2) is a member of the RHO subclass of RAS superfamily GTPases required for proper immune function. An activating mutation in a key switch II region of RAC2 (RAC2

Indexed as

Mutation, MissenseAmino Acid SubstitutionEnzyme ActivationGuanosine TriphosphateHumansHydrolysisNADPH Oxidase 2p21-Activated KinasesProtein DomainsProto-Oncogene Proteins p21(ras)RAC2 GTP-Binding Proteinrac GTP-Binding ProteinsCYBB protein, humanGuanosine TriphosphateKRAS protein, humanNADPH Oxidase 2p21-Activated KinasesProto-Oncogene Proteins p21(ras)RAC2 GTP-Binding Proteinrac GTP-Binding Proteinsdedicator of cytokinesis (DOCK)GTPase-activating protein (GAP)guanine nucleotide exchange factor (GEF)immunodeficiencymolecular dynamicsmolecular dynamics simulationsNADPH oxidaseNADPH oxidase (NOX2)nucleotide exchange factor (GEF)p21-activated kinase (PAK)RASRas proteinRas-related C3 botulinum toxin substrate 2 (RAC2)serine/threonine-protein kinase PAK1T-cell lymphoma and metastasis 1 (TIAM1)

Identifiers

PMID32636302
PMCPMC7443499
OpenAlexW3041274638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.